Therapeutic evaluation of hormone replacement therapy with combination of Fosamax and alone use of Fosamax in osteoporosis and steopenia of perimenopausal women

Abstract

Objective To explore the efficacy and safety of hormone replacement therapy with combination of Fosamax and simple use of Fosamax in osteoporosis and steopenia of perimenopausal women. Methods One hundred and thirteen perimenopausal women with osteoporosis accepted treatment in Outpatient Clinic of Panyu Convalescent Hospital of Guangzhou from December 2010 to June 2014 were chosen and divided into the control group(n=55) and the observation group(n=58) according to therapeutic method.The control group was treated with Fosamax alone while the observation group was treated with HRT basing on the simple use of Fosamax.The therapeutic effect, lumbar and hip bone mineral density(BMD) level, tibial ultrasound velocity(SOS) and T values of tibia, gonadal hormone concentrations, endometrial thickness and adverse reaction of the two groups before and after the therapy were compared. Results (1)The total effective rate of the observation group after the treatment was 93.10%, significantly higher than that of the control group(78.18%, χ2=3.829, P=0.034). (2)Before and after treatment in two groups, there were statistically significant differences in terms of lumbar spine BMD, hip BMD, SOS of tibia, blood follicle stimulating prime(FSH) and estradiol(E2)(P<0.05), and there were statistically significant differences between the two groups after the treatment in terms of lumbar spine BMD, hip BMD, SOS of tibia, FSH and E2(t=3.389, 5.012, 3.997, 5.829, 3.902; P=0.035, 0.028, 0.033, 0.024, 0.038). (3)There was statistically significant differences in term of the incidence of adverse reactions between the observation group and the control group(6.90% vs. 16.36%; χ2=8.273, P=0.012). Conclusion Compared with alone use of Fosamax, the therapeutic effect of hormone replacement therapy with combination of Fosamax and in osteoporosis and steopenia of perimenopausal women is more significant with low occurrence rate of adverse reaction.It is worth popularization. Key words: Osteoporosis in perimenopausal women; Hormone replacement therapy; Fosamax; Bone mineral density